| Drug General Information |
| Drug ID |
D0SL8T
|
| Former ID |
DPR000177
|
| Drug Name |
ISIS-FGFR4
|
| Drug Type |
Antisense drug
|
| Indication |
Obesity [ICD9: 278; ICD10:E66]
|
Preclinical |
[1]
|
|---|
| Company |
ISIS Pharm
|
| Target and Pathway |
| Target(s) |
mRNA of FGFR4 |
Target Info |
|
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
PANTHER Pathway
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
FGF signaling pathway
|
|
Reactome
|
PI3K Cascade
|
|
PIP3 activates AKT signaling
|
|
FGFR4 ligand binding and activation
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Phospholipase C-mediated cascade
|
|
FRS-mediated FGFR4 signaling
|
|
SHC-mediated cascade:FGFR4
|
|
PI-3K cascade:FGFR4
|
|
Negative regulation of FGFR4 signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Signaling by FGFR
|
| References |
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). |
|---|
